サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018

医薬品リーダーシリーズ:トップ50医薬品製造受託機関(CMO)市場2018

レポート概要

医薬品製造受託は医薬品アウトソーシング業界の中で最大のセクターです。医薬品メーカーは医薬品開発、販売におけるコアコンピタンスに資源を集約するために、製造受託のメリット‐コスト低減、高いフレキシビリティ、社外の専門知識−を利用する方法を模索しています。

CMOは医薬品メーカーにとってますます戦略的パートナーとしての地位が確立され、医薬品のライフサイクル全体を通して製剤開発および製造のためのサービスのワンストップショップとなっています。ほぼ全てのサービスを世界規模で提供するために買収や施設拡充によって市場をリードするCMOが成長しています。

一方で、専門性の高いCMO、特に生物学的製剤の製造サービスを提供しているCMOが果たすべき役割はまだ残っています。この最新調査レポートは世界的に市場をリードしている企業について、この数年間に用いてきた戦略と共に分析します。Visiongainの調査、分析レポートはトップ50医薬品製造受託機関にとってのビジネスチャンスと課題について深く掘り下げます。

このレポートがもたらすメリット

読み進めるにつれて今後このセクターに出現するビジネスチャンスを掴む方法が明らかになります。

257ページのレポートに189の図表、グラフを掲載‐これらは全て、他のどこからも入手できないものです。

このレポートは大手医薬品製造受託機関について明確で詳細な見識を与えます。市場に影響を与える主な推進要因と課題を示します。

レポート詳細

目次

1. Report Overview
1.1 Leading Contract Manufacturing Organizations (CMOs) Overview
1.2 Benefits of This Report
1.3 How This Report Delivers Information
1.4 Main Questions This Report Answers
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing, 2017
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2017
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing
2.3.1 Pharmaceutical Contract Manufacturing: Market Drivers
2.3.2 Pharmaceutical Contract Manufacturing: Market Restraints

3. Leading Contract Manufacturing Organizations
3.1 Alcami Corporation - A Contract Development and Manufacturing Organization
3.1.1 Alcami: Manufacturing Services and Capabilities
3.1.2 Divisional Segmentation - Breakdown of Alcami’s Service
3.1.3 Alcami Focuses on Advancing its Analytical Testing Turnaround Time
3.1.4 Alcami Extended its Laboratory Service Program
3.1.5 Alcami: Madison Dearborn Partners
3.1.6 Alcami Expands its Sales Office
3.1.7 Alcami Partnered with Solasia Pharma for Manufacturing Active Pharmaceutical Ingredient
3.2 AbbVie Contract Manufacturing
3.2.1 AbbVie Offers Full-Service Contract Manufacturing
3.2.2 Expanding and Adding New Services: 2017-2018
3.2.3 Biologics and HPAPIs Opportunities for Growth 2017-2028
3.3 Aenova Group
3.3.1 Acquisition of Haupt Creates European CMO Giant
3.3.2 Aenova’s Ever Expanding Manufacturing Capacity
3.3.3 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2017
3.3.4 Aenova: New Manufacturing Facilities to Expand Geographic Presence
3.4 Aesica Pharmaceuticals
3.4.1 Aesica Manufactures APIs and Finished Dosage Forms
3.4.2 Acquisitions Drive Revenue Growth, 2012-2017
3.4.3 Partnering with Academia for Innovative Solutions
3.4.4 Growth through Acquisitions and Internal Expansion
3.4.5 Aesica: Opportunities for Expansion
3.5 Ajinomoto Althea, Inc.
3.5.1 Ajinomoto Althea Expands its Manufacturing Capabilities
3.5.2 Ajinomoto: New U.S. Patent for Manufacturing Crystal Monoclonal Antibodies
3.5.3 Ajinomoto Althea Expanding its Manufacturing Capacity
3.6 Albany Molecular Research, Inc.
3.6.1 Acquiring New Businesses to Expand Capabilities and Services
3.6.2 Expanding Business Operations in New Geographies
3.6.3 Collaborations to Enhance Services
3.6.4 AMRI Acquisition of Euticals S.p.a
3.7 Alkermes
3.7.1 Collaboration as a Growth Strategy to Develop and Commercialize Products
3.7.2 Alkermes: Clinical Development Program
3.8 Almac Group
3.8.1 Almac’s Manufacturing Services
3.8.2 Almac Adding Capacity Globally
3.8.3 New Services Added 2012-2016
3.8.4 Almac Group: Contract Manufacturing Market Outlook
3.9 Amatsigroup
3.9.1 Amatsi: Contract Manufacturing Agreement
3.9.2 Mergers and Acquisitions to Enhance Market Presence
3.9.3 Amatsigroup Expands its Operations and Product Portfolio
3.10 Aurobindo Pharma
3.10.1 API Manufacturing Services
3.10.2 Aurobindo Pharma: Steady Revenue Growth 2012-2017
3.10.3 Aurobindo Expanding Outside of Antibacterial
3.10.4 Aurobindo: Opportunities for Expansion
3.11 Avid Bioservices, Inc.
3.11.1 Avid Focuses on Expanding its Manufacturing Capacity
3.11.2 Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture
3.11.3 Avid Bioservices Expands Process Development Capabilities and Laboratory Infrastructure
3.12 Bayer Healthcare AG
3.12.1 Bayer Focuses on Providing Superior Pharmaceutical Services
3.12.2 Bayer Focuses Quality for all the Products and Services Offered by the Company
3.13 Baxter BioPharma Solutions
3.13.1 BioPharma Solutions Offers a Broad Product Portfolio of Sterile Contract Manufacturing Services and Solutions
3.13.2 BioPharma Focuses on Expanding its Manufacturing Capacities
3.13.3 Baxter BioPharma Solutions and SAFC Collaborate on Complete ADC Offering
3.13.4 Baxter BioPharma Solutions Focuses on Research & Development Investments
3.13.5 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
3.13.6 Baxter BioPharma SWOT Analysis
3.14 Biomay AG
3.14.1 Biomay Offers Fully Integrated GMP Capacities
3.14.2 Biomay Focuses on Increasing its Capital
3.15 Boehringer Ingelheim Contract Manufacturing
3.15.1 Expanding Biopharmaceuticals Manufacturing Services in China
3.15.2 Production Through to Fill and Finished Biopharmaceuticals
3.15.3 A Track Record of Production for 29 Biopharma Products
3.15.4 Increasing Revenue from Contract Manufacturing, 2012-2017
3.15.5 Pulling Out of Small Molecule API Manufacturing
3.15.6 Expanding through New Services
3.15.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth
3.16 Catalent Pharma Solutions - the World’s Leading CMO
3.16.1 Catalent: Manufacturing Services and Capabilities
3.16.2 Divisional Segmentation -Catalent’s Service
3.16.3 Catalent Pharma’s Revenue Growth, 2012-2017
3.16.4 Catalent Is Expanding its Soft Gel Technologies Division
3.16.5 Quadrupling Biopharmaceutical Manufacturing Capacity
3.16.6 Expansion of Packaging Services in Asia-Pacific and Europe: 2015
3.16.7 Adding New Early-Stage Development Services
3.16.8 Expansion in Japan - Growth Prospects for Catalent
3.16.9 New Business Contracts 2014-2016
3.16.10 Catalent: Opportunities for Growth
3.17 Charles River Laboratories International, Inc.
3.17.1 Charles River Laboratories Focuses on Increasing the Service Areas of its Offerings
3.17.2 Strategic Acquisitions as a Growth Strategy to Expand Product Portfolio
3.17.3 Charles River Laboratories Revenue Growth, 2012-2017
3.18 Cardinal Health, Inc.
3.18.1 Cardinal Health Focuses on Helping Healthcare Organizations for Patient Safety
3.18.2 Cardinal Revenue Growth, 2012-2017
3.19 CordenPharma International
3.19.1 CordenPharma Service Division
3.19.2 CordenPharma Emerging in the API Market
3.19.3 Investments in Highly Potent Capabilities
3.19.4 CordenPharma: SWOT Analysis
3.20 Daito Pharmaceutical Co., Ltd.
3.20.1 Daito Has a Portfolio of More than 43 APIs
3.20.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2012-2017
3.20.3 Daito Is Well-Placed for Asian Market Growth - SWOT Analysis
3.21 Delpharm
3.21.1 Finished Dosage Form Manufacturing for Developed Markets
3.21.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2012-2017
3.21.3 Delpharm: Outlook and Prospects for Growth
3.22 Divis Laboratories
3.22.1 Divis Laboratories and the Contract Manufacturing Industry
3.22.2 Divis Laboratories: A Rapidly Growing CMO, 2012-2017
3.22.3 Divis Laboratories: API Manufacturing
3.23 Dr. Reddy’s Laboratories Ltd.
3.23.1 API and FDF Manufacturing Services
3.23.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2012-2017
3.23.3 Advancing in Complex Drug Manufacturing
3.23.4 Expanding in the European Manufacturing Market
3.24 DPT Laboratories, Ltd.
3.24.1 Mylan Acquires Topicals-Focused Specialty and Generic Business of DPT
3.24.2 DPT Enhances Flexibility and Efficiencies
3.24.3 DPT Enhances Capabilities with New High-Speed Filling Center
3.25 Esteve Qu`mica
3.25.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
3.25.2 Expanding in the US, 2016
3.25.3 Esteve Química: SWOT Analysis
3.26 Evonik Degussa
3.26.1 Investing in API and Drug Delivery Services
3.26.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2012-2017
3.26.3 Evonik Is a HPAPI Specialist
3.26.4 Evonik Continues to Grow Across All Segments
3.26.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
3.27 FAMAR Health Care Services
3.27.1 Famar Is an Expert in Lyophilisation
3.27.2 Sustained Growth in Famar’s Revenue: 2011-2016
3.27.3 Expanding Outside Europe
3.27.4 Further Site Acquisitions Are an Opportunity for Growth
3.28 Fareva Group
3.28.1 Fareva Has 35 Years’ Manufacturing Experience
3.28.2 Revenue Growth through Acquisitions: 2012-2017
3.28.3 Fareva SWOT Analysis
3.29 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
3.29.1 Opening of New Manufacturing facility
3.29.2 Fujifilm Establishes Cell Culture Process Development Laboratories
3.29.3 Fujifilm Completes Acquisition of Kalon Biotherapeutics LLC
3.30 GlaxoSmithKline plc
3.30.1 GSK Enters into an Agreement with Novartis for Full Ownership of Consumer Healthcare Business
3.30.2 GSK Received Complete Response from FDA for Candidate Pandemic H5N1 Adjuvanted Influenza Vaccine
3.31 Pfizer CentreOne
3.31.1 Pfizer CentreSource: Historic Revenue Performance, 2012-2017
3.31.2 Will Hospira Acquisition Lead to Revenue Growth in Future?
3.32 Huapont Pharmaceutical Co., Ltd.
3.32.1 China Pharmaceutical Trade
3.33 Lonza
3.33.1 Lonza Is a Leader in Biologics Manufacturing
3.33.2 Lonza Contract Manufacturing and Development: 2012-2017
3.33.3 Investing in Advanced Biological Drug Sectors
3.33.4 The Promise of Antibody-Drug Conjugates (ADCs)
3.33.5 The Regenerative Medicine Future in Japan
3.33.6 Lonza: SWOT Analysis
3.34 Nipro Corporation: Japan’s Leading CMO
3.34.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
3.34.2 Nipro Revenues 2012-2017
3.34.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis
3.35 Paragon Bioservices, Inc.
3.35.1 Paragon Announced Expansion of its New Manufacturing Facility
3.36 Patheon - One of the Top 3 CMOs
3.36.1 Patheon - Global leader in Pharmaceutical Development Services
3.36.2 Contract Manufacturing Services at Patheon
3.36.3 Steady Revenue Growth 2012-2017
3.36.4 DPx Holdings: Developments
3.36.5 Adding New Formulations and Formulation Development Services
3.36.6 Expanding Services Through Acquisition, 2016
3.36.7 Patheon: SWOT Analysis
3.37 Recipharm
3.37.1 Contract Development and Manufacturing Services
3.37.2 Recipharm: Financial Performance 2012-2017
3.37.3 Recipharm Invests in Facility Expansion
3.37.4 Recipharm Growing in the Development and Technology Market Through Acquisitions
3.37.5 Recipharm: SWOT Analysis
3.38 F. Hoffman-La Roche Ltd.
3.38.1 Amplified Revenue Growth in Pharma Manufacturing 2012-2017
3.38.2 Value of Innovation
3.38.3 Approvals and Extensions in Pharmaceuticals Division
3.38.4 Launch of New Products Drive the Growth of the Company
3.39 Royal DSM
3.39.1 Amplified Revenue Growth in Pharma Manufacturing 2012-2017
3.39.2 DSM Pharmaceuticals Products/DPx Holdings: Manufacturing Services
3.39.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
3.39.4 DPx Holdings: A New Pharma Leader
3.39.5 Investing in Biopharma Manufacturing
3.39.6 Expanding API Manufacturing
3.39.7 Generics and Biologics Offer Room for Growth
3.40 Shandong Xinhua Pharmaceutical
3.40.1 Experience in APIs and Finished Dosage Forms
3.40.2 Shandong Xinhua: Strong Revenue Growth 2012-2017
3.40.3 Growing through Joint Ventures
3.40.4 Looking to Expand in the US and EU
3.41 Siegfried
3.41.1 Siegfried’s Acquisitions, 2012-2017
3.41.2 Expanding Siegfried’s Manufacturing Footprint Globally
3.41.3 Expanding High Potency API Capabilities
3.41.4 Siegfried: Financial Performance 2012-2017
3.41.5 Siegfried’s Characteristics within the Contract Manufacturing Market: SWOT Analysis
3.42 TEVA Pharmaceutical, Ltd.
3.42.1 API Manufacturing Services
3.42.2 Teva API: Financial Performance 2012-2017
3.42.3 Building a Footprint in Mexico, India and China
3.42.4 Teva API: SWOT Analysis
3.43 Therapure Biopharma, Inc.
3.43.1 Therapure Collaborated with 3SBio Inc., and CPE Funds
3.44 UPM Pharmaceuticals
3.45 Vetter Pharmaceutical
3.45.1 Vetter is an Injectable Manufacturing Specialist
3.45.2 Services, Collaborations and Differentiating Factors
3.45.3 Expanding Services in the US and Asia
3.45.4 Biologics: Opportunity for Growth for Vetter
3.46 Xcelience, LLC
3.47 Xcellerex, Inc.
3.48 Piramal Pharma Solutions
3.48.1 Mergers and Acquisitions
3.48.2 Piramal Pharma Solutions: Financial Performance 2012-2017
3.48.3 Investment in Technology-based Delivery Platforms
3.48.4 Quality Governance
3.49 Zhejiang Hisun Pharmaceutical
3.49.1 API Manufacturing for Markets Worldwide
3.49.2 Moving into International Drug Marketing
3.49.3 Zhejiang Hisun: Opportunities for Growth
3.50 Zhejiang Huahai Pharmaceuticals
3.50.1 Zhejiang Huahai is a Market Leader Within the Antihypertensive API Market
3.50.2 Zhejiang Huahai: Contract Manufacturing Performance 2012-2017
3.50.3 Expanding in the US Generic Drugs Market
3.50.4 Zhejiang Huahai: SWOT Analysis

4. Conclusions of the Study
4.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
4.2 Strategies for Growth: Prospects for Leading CMOs
4.3 High Demand for Biopharmaceutical Manufacturing Services
4.4 Investing in Novel Technologies
4.5 Outlook for API Manufacturers

Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 2.1 Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2017
Table 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2015-2017
Table 2.3 Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2017
Table 3.1 Alcami Details, 2017
Table 3.2 Alcami Facility Details, 2017
Table 3.3 AbbVie Contract Manufacturing: Details, 2017
Table 3.4 AbbVie Contract Manufacturing Facility Capabilities, 2017
Table 3.5 AbbVie Contract Manufacturing SWOT Analysis, 2017
Table 3.6 Aenova Group Details, 2017
Table 3.7 Aenova Group Manufacturing Capacity by Dosage Form, 2017
Table 3.8 Aenova Group Manufacturing Facility Details, 2017
Table 3.9 Aenova Group SWOT Analysis, 2017
Table 3.10 Aesica Details, 2017
Table 3.11 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2012-2017
Table 3.12 Aesica SWOT Analysis, 2018
Table 3.13 Ajinomoto Althea, Inc. Details, 2017
Table 3.14 Albany Molecular Research, Inc. Details, 2017
Table 3.15 Alkermes Details, 2017
Table 3.16 Almac Details, 2017
Table 3.17 Almac Pharmaceutical Manufacturing Facilities Details, 2017
Table 3.18 Almac: SWOT Analysis, 2017
Table 3.19 Amatsigroup Details, 2017
Table 3.20 Aurobindo Pharma Details, 2016
Table 3.21 Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.22 Aurobindo Contract Manufacturing: SWOT Analysis, 2017
Table 3.23 Avid Bioservices, Inc. Details, 2017
Table 3.24 Bayer Healthcare AG Details, 2017
Table 3.25 Baxter BioPharma Solutions Details, 2017
Table 3.26 Baxter BioPharma Solutions: Facilities and Services Offered, 2016
Table 3.27 Baxter BioPharma Solutions SWOT Analysis, 2017
Table 3.28 Biomay AG Details, 2017
Table 3.29 Boehringer Ingelheim Biopharmaceuticals Details, 2017
Table 3.30 Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2017
Table 3.31 Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
Table 3.32 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2012-2017
Table 3.33 Boehringer Ingelheim: SWOT Analysis, 2017
Table 3.34 Catalent Details, 2017
Table 3.35 Catalent Facility Details, 2017
Table 3.36 Catalent Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2012-2017
Table 3.37 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2017
Table 3.38 Catalent Pharma SWOT Analysis, 2017
Table 3.39 Charles River Laboratories International, Inc. Details, 2017
Table 3.40 Charles River Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2012-2017
Table 3.41 Cardinal Health, Inc. Details, 2017
Table 3.42 Cardinal Health Financial Performance: Revenue ($b), Annual Growth Rates (%), CAGR (%), 2012-2017
Table 3.43 CordenPharma International Details, 2017
Table 3.44 CordenPharma Facilities and Service Details, 2017
Table 3.45 CordenPharma SWOT Analysis, 2017
Table 3.46 Daito Pharmaceutical: Details, 2017
Table 3.47 Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (\m), CAGR (%), 2012-2017
Table 3.48 Daito Pharmaceuticals SWOT Analysis, 2017
Table 3.49 Delpharm Details, 2017
Table 3.50 Delpharm: Facilities and Services, 2017
Table 3.51 Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.52 Delpharm: SWOT Analysis, 2017
Table 3.53 Divis Laboratories Details, 2017
Table 3.54 Divis Laboratories: Facility Details, Production Capacity and Services, 2017
Table 3.55 Divis Laboratories: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.56 Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2017
Table 3.57 Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2017
Table 3.58 Divis Laboratories Contract Manufacturing: SWOT Analysis, 2017
Table 3.59 Dr. Reddy’s Laboratories Ltd. Details, 2017
Table 3.60 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 2017
Table 3.61 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.62 Dr. Reddy’s Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2017
Table 3.63 Dr. Reddy’s Laboratories: SWOT Analysis, 2017
Table 3.64 DPT Laboratories Ltd. Details, 2017
Table 3.65 Esteve Química Details, 2017
Table 3.66 Esteve Química SWOT Analysis, 2017
Table 3.67 Evonik Degussa Details, 2017
Table 3.68 Evonik Health and Nutrition: R&D and Production Sites by Region, 2017
Table 3.69 Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2012-2017
Table 3.70 Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2017
Table 3.71 Famar Details, 2017
Table 3.72 Famar Pharmaceutical Manufacturing Facilities, 2017
Table 3.73 Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
Table 3.74 Famar: SWOT Analysis, 2017
Table 3.75 Fareva Details, 2016
Table 3.76 Fareva Manufacturing Facilities, 2017
Table 3.77 Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.78 Fareva: SWOT Analysis, 2017
Table 3.79 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Details, 2017
Table 3.80 GlaxoSmithKline plc Details, 2017
Table 3.81 Pfizer CentreOne Details, 2017
Table 3.82 Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.83 Pfizer CentreOne SWOT Analysis, 2017
Table 3.84 Huapont Pharmaceutical Co., Ltd. Details, 2017
Table 3.85 Lonza Details, 2017
Table 3.86 Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
Table 3.87 Lonza Pharma & Biotech Department: Revenue ($m), 2012-2018
Table 3.88 ADCs Approved and in Late Stage Clinical Development, 2014
Table 3.89 Lonza SWOT Analysis, 2017
Table 3.90 Nipro Pharma Details, 2017
Table 3.91 Nipro Pharmaceutical Contract Manufacturing Capabilities: 2012-2017
Table 3.92 Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2017
Table 3.93 Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2012-2017
Table 3.94 Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2017
Table 3.95 Paragon Bioservices, Inc. Details, 2017
Table 3.96 Patheon Details, 2017
Table 3.97 Patheon Manufacturing Facilities, 2017
Table 3.98 Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2012-2017
Table 3.99 Patheon: SWOT Analysis, 2017
Table 3.100 Recipharm Details, 2017
Table 3.101 Recipharm: Facility Details and Services, 2017
Table 3.102 Recipharm: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2012-2017
Table 3.103 Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2017
Table 3.104 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2017
Table 3.105 Recipharm: SWOT Analysis, 2017
Table 3.106 F. Hoffman-La Roche Details, 2017
Table 3.107 Roche Pharmaceutical Manufacturing: Revenue ($bn), Annual Growth (%), CAGR (%) 2012-2017
Table 3.108 Royal DSM Details, 2017
Table 3.109 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%) 2012-2017
Table 3.110 DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
Table 3.111 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2012-2017
Table 3.112 DSM Pharmaceutical Manufacturing: SWOT Analysis, 2017
Table 3.113 Shandong Xinhua Pharmaceuticals Details, 2017
Table 3.114 Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2017
Table 3.115 Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.116 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2017
Table 3.117 Shandong Xinhua Manufacturing: SWOT Analysis, 2017
Table 3.118 Siegfried Details, 2017
Table 3.119 Siegfried Pharmaceutical Manufacturing Facilities Details, 2017
Table 3.120 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2012-2017
Table 3.121Siegfried: SWOT Analysis, 2017
Table 3.122 Teva API Details, 2017
Table 3.123 Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.124 Teva API SWOT Analysis, 2017
Table 3.125 Therapure Biopharma Details, 2017
Table 3.126 UPM Pharmaceuticals Details, 2017
Table 3.127 Vetter Details, 2017
Table 3.128 Vetter Pharmaceutical Facilities, 2017
Table 3.129 Vetter: SWOT Analysis, 2017
Table 3.130 Xcelience LLC Details, 2017
Table 3.131 Xcellerex, Inc. Details, 2017
Table 3.132 Piramal Pharma Solutions Details, 2017
Table 3.133 Piramal Pharma Solutions: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.134 Zhejiang Hisun Pharmaceuticals Details, 2017
Table 3.135 Zhejiang Hisun Manufacturing: SWOT Analysis, 2017
Table 3.136 Zhejiang Huahai Pharmaceuticals Details, 2017
Table 3.137 Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
Table 3.138 Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2017
Table 4.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017

List of Figures
Figure 2.1 Selected Services Contracted to CMOs by Developmental Stage, 2017
Figure 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), 2015-2017
Figure 2.3 Contract Manufacturing Market by Leading Country: Market Share (%), 2017
Figure 2.4 Pharmaceutical Contract Manufacturing: Drivers and Restraints
Figure 3.1 Aesica Pharmaceuticals: Revenue ($m), 2012-2017
Figure 3.2 Aurobindo Contract Manufacturing: Revenue ($m), 2012-2017
Figure 3.3 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
Figure 3.4 Catalent Facilities by Region, 2017
Figure 3.5 Catalent Facilities by Service Offered, 2017
Figure 3.6 Catalent Financial Performance: Revenue ($m), 2012-2017
Figure 3.7 Catalent Financial Performance by Product Type: Revenue Share (%), 2017
Figure 3.7 Charles River Laboratories Financial Performance: Revenue ($m), 2012-2017
Figure 3.8 Cardinal Health Financial Performance: Revenue ($b), 2012-2017
Figure 3.9 Daito Pharmaceuticals Financial Performance: Revenue ($m), 2012-2017
Figure 3.10 Delpharm: Revenue ($m), 2012-2017
Figure 3.11 Divis Laboratories Contract Manufacturing: Revenue ($m), 2012-2017
Figure 3.12 Divis Laboratories Revenue Distribution: Revenue ($m), 2017
Figure 3.13 Divis Laboratories Revenue by Region: Share of Total (%), 2017
Figure 3.14 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 2017
Figure 3.15 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2012-2017
Figure 3.16 Dr. Reddy’s Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2017
Figure 3.17 Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2017
Figure 3.18 Evonik Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
Figure 3.19 Famar Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
Figure 3.20 Fareva Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
Figure 3.21 Pfizer CentreOne: Revenue ($m), 2012-2017
Figure 3.22 Lonza Pharma & Biotech: Revenue ($m), 2012-2018
Figure 3.23 Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2017
Figure 3.24 Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2012-2017
Figure 3.25 Nipro Pharmaceuticals Financial Performance: Revenue ($m), 2012-2017
Figure 3.26 Patheon Pharmaceutical Development Projects (%) by Phase, 2017
Figure 3.27 Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2017
Figure 3.28 Patheon Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
Figure 3.29 Recipharm: Revenue ($m), 2012-2017
Figure 3.30 Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2017
Figure 3.31 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2017
Figure 3.32 Roche Pharmaceutical Manufacturing: Revenue ($b), 2012-2017
Figure 3.33 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
Figure 3.34 DSM Pharmaceutical Products (DPP)/ DPx Holdings Division: Revenue ($m), 2011-2016
Figure 3.35 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2012-2017
Figure 3.36 Shandong Xinhua: Revenue ($m), 2012-2017
Figure 3.37 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2017
Figure 3.38 Siegfried Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
Figure 3.39 Teva API: Revenue ($m), 2012-2017
Figure 3.40 Piramal Pharma Solutions: Revenue ($m), 2012-2017
Figure 3.41 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2012-2017
Figure 4.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2012-2017

発刊日

2018/09/28

体裁

PDF / 257ページ

販売価格

2,699GBP

発行

Visiongain

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

関連カテゴリ

医薬品原料・製剤 / アウトソーシング

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE